Navigation Links
VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
Date:12/14/2010

glycemic control and improvement in cardiovascular risk factors, when used in combination with a diet and lifestyle modification program.

About Obesity

Obesity is a chronic condition defined by having excess body fat. Obesity significantly increases the risk of developing many different diseases and health conditions, including type 2 diabetes, hypertension, metabolic syndrome, cardiovascular disease, some cancers and osteoarthritis. According to a report in The Lancet in 2009, morbid obesity shortens life expectancy by approximately 10 years, and moderate obesity shortens it by approximately 3 years.

Approximately one-third of American adults (more than 72 million people) are obese, and many more are overweight with co-morbidities. Beyond its impact on health, obesity accounts for 9.1% of US annual health care spending – nearly $150 billion.

About VIVUS

VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead product in clinical development, QNEXA®, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US regulators. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on VIVUS' cur
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. VIVUS to Present at Two Upcoming Investor Conferences
2. VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results
3. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
4. VIVUS Announces Sale of MUSE Assets to Meda
5. VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
6. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
7. VIVUS to Present at Lazard Capital Markets Healthcare Conference
8. VIVUS Announces Promotion of Peter Tam to President
9. Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting
10. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
11. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... SAN FRANCISCO , June 29, ... company,s novel blood-draw technology has received CE Mark ... quality from the European Union. This regulatory milestone ... alternative to one of the most common procedures ... Velano Vascular,s proprietary device reduces the ...
(Date:6/29/2015)... , June 29, 2015 ... and predicted revenues ,Where is the market for dermatological ... market? Visiongain ,s new report shows you potential ... and prospects. Our 310 page report ... most lucrative areas in the industry and the future ...
(Date:6/29/2015)... Calif. , June 29, 2015  The ... innovative features to cars on the basis of ... The industry is now on the verge of ... cars. While automotive HWW non-critical features such as ... be present in 30 to 40 percent of ...
Breaking Medicine Technology:Velano Vascular Receives CE Mark For Novel Blood Draw Technology Designed to Reduce Needle Exposures for Hospitalized Patients and Healthcare Providers 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 3Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 4Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 5Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 6Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 7Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 8Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 2Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 3Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 4
... Expected in November 2008, BOTHELL, Wash., Oct. 9 ... the completion of patient enrollment and dosing,for the third ... and,efficacy of its formulation of 12-hour extended-release (ER) ibuprofen ... top-line,results from this pivotal trial in November 2008. Ibuprofen ...
... Will Reduce Animal Use in Cosmetics and Chemicals ... Corp. today announced,that results of a recently completed ... EpiDerm in vitro human skin tissue,equivalent. The test ... to be accepted as a validated alternative to ...
Cached Medicine Technology:SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 3MatTek's EpiDerm In Vitro Tissues Headed for Validation in Europe 2
(Date:6/29/2015)... , ... June 29, 2015 , ... ... C. Cook, to its multidisciplinary group of physicians and specialists. Dr. Cook is ... provide quality healthcare in hopes of achieving outstanding medical outcomes. , “We are ...
(Date:6/29/2015)... ... 29, 2015 , ... Lake Balboa Care Center announced today ... prestigious five-star, premium rating from Medicare. Medicare’s ratings are based on three criteria, ... indicative of its commitment to providing patients with a safe, clean, and comfortable ...
(Date:6/29/2015)... ... June 29, 2015 , ... Human Factors and ... July 16, 2015 — 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/humanfactors ... factors engineering to the design of new products as well as to postmarket ...
(Date:6/29/2015)... ... June 29, 2015 , ... With Urgent Care Medicine now serving a vital ... Board of Urgent Care Medicine and the Medical Society of Delaware to provide its ... physicians and health care professionals. , According to Matthew Bader, Exam Master CEO and ...
(Date:6/29/2015)... ... June 29, 2015 , ... The world’s fastest and highest ... Museum to the Science Museum of Virginia. This iconic, supersonic stealth plane will become ... “Suspending a supersonic jet from the ceiling of a historic train station is perhaps ...
Breaking Medicine News(10 mins):Health News:Healthpointe in La Tijera Proudly Announces the Addition of a New Chiropractor 2Health News:Healthpointe in La Tijera Proudly Announces the Addition of a New Chiropractor 3Health News:Lake Balboa Releases New Facility Video of Patient Testimonials 2Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 2Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 3Health News:Exam Master Partners to Provide New Urgent Care Continuing Medical Education Resource 2Health News:Exam Master Partners to Provide New Urgent Care Continuing Medical Education Resource 3Health News:SR-71 Prepares for Flight to Science Museum of Virginia 2
... ... Drexel University in November , ... Philadelphia, PA (PRWEB) November 11, 2009 -- Drexel University Online ... for demonstrating its commitment to training and development through various forms of eLearning to ...
... ... services, Ms. McKenna and the Beyond the Box team can assist seniors and their loved ... ... Washington, DC based relocation and design firm, Beyond the Box , is pleased to ...
... ... ECG core lab market with largest number of highly automated QT(sm) studies. , ... Rochester, NY (PRWEB) November ... services and QT analysis, announced today that a top five pharmaceutical company has awarded ...
... of workplace exposure to Bisphenol-A may increase the risk of ... study appearing online in the journal Human Reproduction, ... study examined 634 workers in factories in China, comparing workers ... in factories where no BPA was present. The study found ...
... Emory University Rollins School of Public Health researchers ... at the American Public Health Association,s annual meeting in ... employees participating in a large-scale worksite wellness program. ... are highlighted below. Does faith affect how ...
... 10 Centene Corporation (NYSE: CNC ) announced ... Massachusetts Inc.(TM) (CeltiCare), and representatives from the Health Connector, ... affordable healthcare for all Massachusetts consumers. , In ... on schedule and on a voluntary basis. CeltiCare ...
Cached Medicine News:Health News:Catholic Health East Named 2009 National Distance Learning Week Award Recipient 2Health News:Catholic Health East Named 2009 National Distance Learning Week Award Recipient 3Health News:Relocation Specialists Beyond the Box Team With Nurse to Help Facilitate Senior Moves 2Health News:Relocation Specialists Beyond the Box Team With Nurse to Help Facilitate Senior Moves 3Health News:Top Five International Pharmaceutical Company Awards Comprehensive Cardiac Safety Study to iCardiac 2Health News:Workplace BPA Exposure Increases Risk of Male Sexual Dysfunction, Kaiser Permanente Study Finds 2Health News:Workplace BPA Exposure Increases Risk of Male Sexual Dysfunction, Kaiser Permanente Study Finds 3Health News:Workplace BPA Exposure Increases Risk of Male Sexual Dysfunction, Kaiser Permanente Study Finds 4Health News:Workplace BPA Exposure Increases Risk of Male Sexual Dysfunction, Kaiser Permanente Study Finds 5Health News:Worksite wellness programs may reduce employee absenteeism 2Health News:CeltiCare Confirms Timetable For Launch of Products With Massachusetts Health Connector 2
... A concentrated enzymatic cleanser ... semi-automated hematology instruments. It ... all Abbott CELL-DYN® hematology ... instruments. The shelf life ...
Streck-CD3500 Hemoglobin/Lyse is a lytic reagent for the quantitative determination of hemoglobin on the Abbott CELL-DYN® 3500 and 3700. The shelf life is two years from the date of manufacture....
Streck-Diluent III Plus is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 3000, 3500 and 3700. The shelf...
Streck-Diluent IIIA is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 1700. The shelf life is one year f...
Medicine Products: